Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Milestone Pharmaceuticals Inc. reported results from its 2026 annual shareholder meeting. Shareholders approved an amendment to the 2019 Equity Incentive Plan that increases the number of ordinary shares authorized for issuance by 6,800,000 shares, expanding the pool available for future equity-based compensation.
All eight director nominees were elected, each receiving roughly 23.4–24.2 million votes for and about 3.1–3.9 million votes withheld, with 48.6 million broker non-votes recorded per nominee. Shareholders also ratified PricewaterhouseCoopers LLP as auditor with 75,025,285 votes for, 249,836 against and 664,912 abstentions.
They approved the amended 2019 Equity Incentive Plan with 19,262,773 votes for, 5,479,043 against, 2,617,059 abstentions and 48,581,158 broker non-votes. In a non-binding advisory vote on executive pay, 19,665,705 votes supported the compensation of named executive officers, 6,990,920 were against, 702,247 abstained and 48,581,161 were broker non-votes.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Equity plan share increase: 6,800,000 shares
Auditor ratification votes for: 75,025,285 votes
Auditor votes against: 249,836 votes
+4 more
7 metrics
Equity plan share increase
6,800,000 shares
Additional ordinary shares authorized under 2019 Equity Incentive Plan
Auditor ratification votes for
75,025,285 votes
Ratification of PricewaterhouseCoopers LLP as auditor
Auditor votes against
249,836 votes
Ratification of PricewaterhouseCoopers LLP as auditor
Equity plan votes for
19,262,773 votes
Approval of amended 2019 Equity Incentive Plan
Equity plan votes against
5,479,043 votes
Approval of amended 2019 Equity Incentive Plan
Say-on-pay votes for
19,665,705 votes
Non-binding advisory vote on executive compensation
Say-on-pay votes against
6,990,920 votes
Non-binding advisory vote on executive compensation
Key Terms
2019 Equity Incentive Plan, broker non-votes, non-binding advisory vote, emerging growth company, +1 more
5 terms
2019 Equity Incentive Plan financial
"approved an amendment to the Company’s 2019 Equity Incentive Plan, as amended"
broker non-votes financial
"as well as the final tally of the number of votes cast ... and broker non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding advisory vote financial
"Proposal 4 was a proposal for a non-binding advisory vote on the compensation"
A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Audit Committee financial
"ratify the selection by the Company’s Audit Committee of PricewaterhouseCoopers LLP"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
FAQ
Were all Milestone Pharmaceuticals (MIST) director nominees elected in 2026?
All eight director nominees were elected to Milestone’s board. Each received approximately 23.4–24.2 million votes for and about 3.1–3.9 million votes withheld, with 48,581,157 or 48,581,158 broker non-votes recorded for each nominee at the 2026 annual meeting.
What were the results of Milestone Pharmaceuticals’ say-on-pay vote in 2026?
In the non-binding advisory vote on executive compensation, Milestone shareholders cast 19,665,705 votes for the named executive officers’ pay and 6,990,920 votes against, with 702,247 abstentions and 48,581,161 broker non-votes, indicating majority support for the company’s compensation practices.